Expert Review of Endocrinology & Metabolism最新文献_第3页

Paraneoplastic endocrine syndromes: a contemporary overview. 副肿瘤内分泌综合征：当代综述。

IF 2.7

Expert Review of Endocrinology & Metabolism Pub Date : 2025-01-01 Epub Date: 2025-01-05 DOI: 10.1080/17446651.2024.2448782

Juan Eduardo Quiroz-Aldave, Jacsel Suarez-Rojas, Elman Rolando Gamarra-Osorio, Katia Rivera-Fabián, María Del Carmen Durand-Vásquez, Luis Alberto Concepción-Urteaga, José Paz-Ibarra, Marcio José Concepción-Zavaleta

{"title":"Paraneoplastic endocrine syndromes: a contemporary overview.","authors":"Juan Eduardo Quiroz-Aldave, Jacsel Suarez-Rojas, Elman Rolando Gamarra-Osorio, Katia Rivera-Fabián, María Del Carmen Durand-Vásquez, Luis Alberto Concepción-Urteaga, José Paz-Ibarra, Marcio José Concepción-Zavaleta","doi":"10.1080/17446651.2024.2448782","DOIUrl":"10.1080/17446651.2024.2448782","url":null,"abstract":"Introduction: Endocrine paraneoplastic syndromes (ePNS) are caused by malignant cells that induce hormonal alterations unrelated to the tissue of origin of the neoplasm. The aim of this manuscript is to review the pathophysiology, diagnosis, and treatment of endocrine paraneoplastic syndromes (ePNS).Areas covered: We searched the PubMed/Medline, Embase, and Scielo databases, including 96 articles. The pathogenesis of ePNS involves mutations that activate hormonal genes. Hypercalcemia, the most common ePNS, is marker of poor prognosis in most cases. The syndrome of inappropriate antidiuresis causes euvolemic hyponatremia. Ectopic Cushing's syndrome is commonly associated with lung cancer. Paraneoplastic acromegaly is very rare and is associated with pancreatic and lung tumors. Paraneoplastic hypoglycemia usually requires surgical treatment. Other endocrine paraneoplastic syndromes include ectopic secretion of hormones such as calcitonin, renin, vasoactive intestinal polypeptide, fibroblast growth factor 23, paraneoplastic autoimmune hypophysitis, and others.Expert opinion: In addition to the local manifestations and metastasis of neoplasms, some secrete bioactive substances causing PNS. Recognizing and treating PNS early improves clinical outcomes. Larger-scale studies and clinical trials are needed to enhance their management and prognosis.","PeriodicalId":12107,"journal":{"name":"Expert Review of Endocrinology & Metabolism","volume":" ","pages":"51-62"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142931098","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Glucocorticoid therapy in classic congenital adrenal hyperplasia: traditional and new treatment paradigms.

IF 2.7

Expert Review of Endocrinology & Metabolism Pub Date : 2025-01-01 Epub Date: 2025-01-27 DOI: 10.1080/17446651.2025.2450423

Irina Bancos, Hyunwoo Kim, Henry K Cheng, Mariam Rodriguez-Lee, Helen Coope, Samantha Cicero, Hannah Goldsmith, Vivian H Lin, George S Jeha

{"title":"Glucocorticoid therapy in classic congenital adrenal hyperplasia: traditional and new treatment paradigms.","authors":"Irina Bancos, Hyunwoo Kim, Henry K Cheng, Mariam Rodriguez-Lee, Helen Coope, Samantha Cicero, Hannah Goldsmith, Vivian H Lin, George S Jeha","doi":"10.1080/17446651.2025.2450423","DOIUrl":"10.1080/17446651.2025.2450423","url":null,"abstract":"Introduction: Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency (CAH) is a rare genetic condition characterized by cortisol deficiency and excess adrenal androgens. CAH treatment is a lifelong balancing act between the need to reduce excess androgens, typically with supraphysiologic glucocorticoid (GC) doses, and concerns about potentially serious GC-related adverse events. Tradeoffs between the consequences of excess androgens versus GCs must be constantly reassessed throughout each patient's lifetime, based on current clinical needs and treatment goals. Adding to this burden are limited treatment options and the need for new CAH medications.Areas covered: This narrative review describes the current challenges of CAH treatment, the potential of new non-GC therapies to reduce excess androgens and thereby allow for lower GC doses, and the potential implications of decreasing GC doses to a more physiologic range (i.e. sufficient to replace missing cortisol, but without the need to reduce androgens).Expert opinion: Even with non-GC therapies, patients' needs will continue to shift throughout their lifetimes. Treatment will therefore always require joint decision-making between physicians and patients. However, over the lifetimes of patients with CAH, any reduction in GC daily dose may have a large cumulative impact in decreasing the GC-related burden of this disease.","PeriodicalId":12107,"journal":{"name":"Expert Review of Endocrinology & Metabolism","volume":" ","pages":"33-49"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143052097","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Fertility preservation options at cancer diagnosis; classifying use and decision-making in the United States. 癌症诊断时保留生育能力的选择；美国的分类使用和决策。

IF 2.7

Expert Review of Endocrinology & Metabolism Pub Date : 2025-01-01 Epub Date: 2025-01-02 DOI: 10.1080/17446651.2024.2448789

Sarita Pathak, Paxton Voigt, Margot Bellon, Susan T Vadaparampil, Gwendolyn P Quinn

{"title":"Fertility preservation options at cancer diagnosis; classifying use and decision-making in the United States.","authors":"Sarita Pathak, Paxton Voigt, Margot Bellon, Susan T Vadaparampil, Gwendolyn P Quinn","doi":"10.1080/17446651.2024.2448789","DOIUrl":"10.1080/17446651.2024.2448789","url":null,"abstract":"Introduction: Incidence rates for cancer among adolescent and young adults (AYA) have increased 30% since 1970. Declines in mortality underscore the importance of discussing fertility preservation (FP) options prior to receiving gonadotoxic treatments. National guidelines outline FP options including oocyte (OC), embryo (EC), and ovarian tissue cryopreservation (OTC) for female AYA patients. Significant progress has led to changes in FP practices, initially limited to EC. Subsequently, OC was deemed non-experimental in 2013, followed by OTC in 2020. Despite these advancements and guideline recommendations, the availability and utilization of FP services vary.Areas covered: Rapid review methodologies were employed to classify trends in female AYAs utilization of FP cryopreservation options following guideline updates. FP options reviewed include OC, EC, and OTC. Additionally, the review examined if aspects of the decision-making process relevant to FP were present.Expert opinion: Ten articles met inclusion criteria. Results suggest that the declassification of OTC has not necessarily increased its use and OC and EC appear to be most frequently used. The factors associated with decision making appear to have remained consistent with financial constraints having the most impact, followed by partner status and concerns about recurrence.","PeriodicalId":12107,"journal":{"name":"Expert Review of Endocrinology & Metabolism","volume":" ","pages":"21-32"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142913497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Adrenocortical tumors and hereditary syndromes. 肾上腺皮质肿瘤和遗传综合征。

IF 2.7

Expert Review of Endocrinology & Metabolism Pub Date : 2025-01-01 Epub Date: 2024-11-21 DOI: 10.1080/17446651.2024.2431748

Kanakamani Jeyaraman, Paola Concolino, Henrik Falhammar

{"title":"Adrenocortical tumors and hereditary syndromes.","authors":"Kanakamani Jeyaraman, Paola Concolino, Henrik Falhammar","doi":"10.1080/17446651.2024.2431748","DOIUrl":"10.1080/17446651.2024.2431748","url":null,"abstract":"Introduction: Adrenocortical tumors (ACTs) are frequently encountered in clinical practice. They vary in clinical and biological characteristics from nonfunctional to life threatening hormone excess, from benign to highly aggressive malignant tumors. Most ACTs appear to be benign and nonfunctioning. It has been controversial how these apparently benign and nonfunctioning tumors should be monitored. Over the past few decades, significant advances have been made in understanding the regulation of growth and tumorigenesis in adrenocortical cells. Defining the molecular pathomechanisms in inherited tumor syndromes led to the expansion of research to sporadic ACTs. Distinct molecular signatures have been identified in sporadic ACTs and a potential genomic classification of ACT has been proposed.Areas covered: In this review, we discuss the various adrenocortical pathologies associated with hereditary syndromes with special focus on their molecular pathomechanisms, the understanding of which is important in the era of precision medicine.Expert opinion: Identifying the molecular pathomechanisms of the adrenocortical tumorigenesis in inherited syndromes has led to the understanding of the alterations in different signaling pathways that help explain the wide variations in the biology and behavior of ACTs.","PeriodicalId":12107,"journal":{"name":"Expert Review of Endocrinology & Metabolism","volume":" ","pages":"1-19"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142681235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Acromegaly: diagnostic challenges and individualized treatment. 肢端肥大症：诊断挑战和个体化治疗。

IF 2.7

Expert Review of Endocrinology & Metabolism Pub Date : 2025-01-01 Epub Date: 2025-01-05 DOI: 10.1080/17446651.2024.2448784

Pamela U Freda

{"title":"Acromegaly: diagnostic challenges and individualized treatment.","authors":"Pamela U Freda","doi":"10.1080/17446651.2024.2448784","DOIUrl":"10.1080/17446651.2024.2448784","url":null,"abstract":"Introduction: Acromegaly is due in almost all cases to a GH-secreting pituitary tumor. GH and IGF-1 excesses lead to its multi-system clinical manifestations and comorbidities. Acromegaly is under-diagnosed and typically presents with advanced disease. When early or mild, clinical recognition and biochemical confirmation are especially challenging. Individualized treatment may optimize patient outcome.Areas covered: This review covers challenges to diagnosing acromegaly and reviews therapies for acromegaly with a focus on those aspects that can be individualized.Expert opinion: The first step in diagnosing acromegaly is recognizing it clinically. To improve this, increase awareness and education of the general population and healthcare professionals about the acromegaly phenotype is needed. Once suspected clinically, IGF-1 measurement is the initial step in making the biochemical diagnosis. GH may be < 1.0 µg/L after oral glucose suppression in early/mild cases. GH and IGF-1 should be considered in concert. Providers should be aware of conditions that can alter GH and IGF-1 levels and each assay's performance. An individualized treatment approach is best employed. Surgery is preferred as initial treatment and medical therapy as initial adjuvant therapy. In individualizing therapy, the advantages and disadvantages of each option and predictors of response to them should be considered.","PeriodicalId":12107,"journal":{"name":"Expert Review of Endocrinology & Metabolism","volume":" ","pages":"63-85"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11832332/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142931067","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Systematic review and meta-analyses of adipokine levels in hypothyroidism: a role for retinol-binding protein 4. 脂肪因子水平在甲状腺功能减退中的系统回顾和荟萃分析：视黄醇结合蛋白4的作用。

IF 2.7

Expert Review of Endocrinology & Metabolism Pub Date : 2025-01-01 Epub Date: 2024-12-09 DOI: 10.1080/17446651.2024.2438231

Emiliana Maria Torres, Mariana Lorena Tellechea

{"title":"Systematic review and meta-analyses of adipokine levels in hypothyroidism: a role for retinol-binding protein 4.","authors":"Emiliana Maria Torres, Mariana Lorena Tellechea","doi":"10.1080/17446651.2024.2438231","DOIUrl":"10.1080/17446651.2024.2438231","url":null,"abstract":"Background: Hypothyroidism (HT) is associated with numerous well-characterized comorbidities and established biomarkers for subclinical atherosclerosis which may lead to an elevated risk of cardiovascular disease; however, the precise molecular mechanism underlying these pathological features remains elusive. Increased levels of adipokines may have adverse effects on multiple atherosclerotic risk factors in HT. Different studies have evaluated the association between HT and adipokines with conflicting results.Methods: A systematic review and meta-analyses were conducted to provide an overview of adipokine levels in HT. The last literature search was done in February 2024 for studies analyzing traditional and novel circulating adipokines levels (excluding resistin and irisin) in patients with HT. The standard mean differences and 95% confidence intervals (CI) were calculated using random-effect models except if no heterogeneity was found.Results: HT was not associated with leptin, adiponectin, omentin-1, visfatin, or apelin levels; however, increased retinol-binding protein 4 (RPB4) levels were found in both overall and subclinical HT (p-values = 0.0002 and 0.004 respectively).Conclusion: While pooled analysis suggested a role for RBP4 in hypothyroid patients, associations do not imply cause-effect relationships, and therefore the potential clinical implications of these findings should await further mechanistic studies.Registration: The protocol has been registered in the Prospective Register of Systematic Reviews (PROSPERO) under the identification number CRD42024537717.","PeriodicalId":12107,"journal":{"name":"Expert Review of Endocrinology & Metabolism","volume":" ","pages":"87-98"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142794615","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Trends and projections of type 2 diabetes mellitus in South Asia: a three-decade analysis and forecast through 2031 using global burden of disease study (1990 - 2021).

IF 2.7

Expert Review of Endocrinology & Metabolism Pub Date : 2025-01-01 Epub Date: 2025-01-07 DOI: 10.1080/17446651.2024.2448790

Vijay Kumar, Quazi Syed Zahiruddin, Diptismita Jena, Roopashree R, Mandeep Kaur, Manish Srivastava, Amit Barwal, G V Siva Prasad, Pranchal Rajput, Vaibhav Jaiswal, Rachna Kathuria, Arun Joshi, Muhammed Shabil, Madhur Taneja, Abhinav Mishra, Alabed Ali Ahmed Alabed, Ganesh Bushi, Rachana Mehta, Sanjit Sah, Abhay M Gaidhane, Prakasini Satapathy

{"title":"Trends and projections of type 2 diabetes mellitus in South Asia: a three-decade analysis and forecast through 2031 using global burden of disease study (1990 - 2021).","authors":"Vijay Kumar, Quazi Syed Zahiruddin, Diptismita Jena, Roopashree R, Mandeep Kaur, Manish Srivastava, Amit Barwal, G V Siva Prasad, Pranchal Rajput, Vaibhav Jaiswal, Rachna Kathuria, Arun Joshi, Muhammed Shabil, Madhur Taneja, Abhinav Mishra, Alabed Ali Ahmed Alabed, Ganesh Bushi, Rachana Mehta, Sanjit Sah, Abhay M Gaidhane, Prakasini Satapathy","doi":"10.1080/17446651.2024.2448790","DOIUrl":"https://doi.org/10.1080/17446651.2024.2448790","url":null,"abstract":"Background: The rapid rise of non-communicable diseases, particularly type 2 diabetes mellitus (T2DM), poses a significant global public health challenge, with South Asia experiencing an increasingly severe burden. This study aimed to analyse historical trends of T2DM across South Asia from 1990 to 2021 and forecast incidence through 2031.Research design and methods: We carried out analysis based on the data from the 2021 Global burden of disease study. Joinpoint regression was used to identify significant changes in trends over time, and ARIMA models were applied to forecast incidence rates.Results: Between 1990 and 2021, the average annual percentage change (AAPC) of age-standardized prevalence rates and incidence rates increased by 2.15 and 1.72 respectively. The age-standardized mortality rate rose more slowly, at 1.05 AAPC, with females experiencing a slightly higher AAPC than males. ARIMA forecasts suggest that by 2031, T2DM incidence rates will continue to rise significantly across all South Asian countries.Conclusions: This study highlights the need for public health policies focused on preventing obesity, promoting physical activity, and improving healthcare access. It also calls for addressing regional disparities in T2DM prevalence and mortality to better allocate resources and prioritize policies to combat the diabetes epidemic inSouth Asia.","PeriodicalId":12107,"journal":{"name":"Expert Review of Endocrinology & Metabolism","volume":"20 1","pages":"99-106"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143432741","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Progress in managing children with achondroplasia. 管理软骨发育不全儿童的进展。

IF 2.7

Expert Review of Endocrinology & Metabolism Pub Date : 2024-11-01 Epub Date: 2024-08-12 DOI: 10.1080/17446651.2024.2390416

Tashunka Taylor-Miller, Ravi Savarirayan

{"title":"Progress in managing children with achondroplasia.","authors":"Tashunka Taylor-Miller, Ravi Savarirayan","doi":"10.1080/17446651.2024.2390416","DOIUrl":"10.1080/17446651.2024.2390416","url":null,"abstract":"Introduction: Achondroplasia is a heritable disorder of the skeleton that affects approximately 300,000 individuals worldwide. Until recently, treatment for this condition has been purely symptomatic. Efficacious treatment options for children are now approved or are in clinical trials.Areas covered: This review discusses key advances in the therapeutic management of children with achondroplasia, including vosoritide, the first approved drug, and other emerging precision therapies. These include navepegritide, a long-acting form of C-type natriuretic peptide, and infigratinib, a tyrosine kinase receptor inhibitor, summarizing trial outcomes to date.Expert opinion: The advent of the first approved precision therapy for achondroplasia in vosoritide has been a paradigm shifting advance for children affected by this condition. In addition to changing their natural growth history, it is hoped that it will decrease their medical complications and enhance functionality. These new treatment options highlight the importance of prompt prenatal identification and subsequent testing of a suspected fetus with achondroplasia and counseling of families. It is hoped that, in the near future, families will have the option to consider a range of effective targeted therapies that best suit their child with achondroplasia, starting from birth should they choose.","PeriodicalId":12107,"journal":{"name":"Expert Review of Endocrinology & Metabolism","volume":" ","pages":"479-486"},"PeriodicalIF":2.7,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141916480","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Environmental factors related to the origin and evolution of differentiated thyroid cancer: a narrative review. 与分化型甲状腺癌的起源和演变有关的环境因素：叙述性综述。

IF 2.7

Expert Review of Endocrinology & Metabolism Pub Date : 2024-11-01 Epub Date: 2024-07-08 DOI: 10.1080/17446651.2024.2377687

José Paz-Ibarra, Marcio José Concepción-Zavaleta, Juan Eduardo Quiroz-Aldave

{"title":"Environmental factors related to the origin and evolution of differentiated thyroid cancer: a narrative review.","authors":"José Paz-Ibarra, Marcio José Concepción-Zavaleta, Juan Eduardo Quiroz-Aldave","doi":"10.1080/17446651.2024.2377687","DOIUrl":"10.1080/17446651.2024.2377687","url":null,"abstract":"Introduction: The global incidence of thyroid cancer (TC) has increased in the last decades. While improvements in diagnosis may contribute, overdiagnosis is also a possibility. This review focuses on the epidemiology, risk factors, and immune microenvironment associated with differentiated TC (DTC).Areas covered: A search was conducted in Scielo, Scopus, and EMBASE databases, involving 72 articles. TC is the most common endocrine neoplasm, with DTC form being predominant. Its incidence has globally risen, particularly among women aged over 45. Endogenous risk factors for DTC include genetic disorders, race, age, female gender, obesity, and type 2 diabetes mellitus. Environmental risks involve ionizing radiation, whether through therapeutic treatment or environmental contamination from nuclear accidents, iodine deficiency, endocrine disruptors, residence in volcanic areas, environmental pollution, and stress. The use of anti-obesity medications remains controversial. The tumor's immune microenvironment is the histological space where tumor cells interact with host cells, crucial for understanding aggressiveness. Immunotherapy emerges as a promising intervention.Expert opinion: Recent advances in DTC management offer transformative potential, requiring collaborative efforts for implementation. Emerging areas like precision medicine, molecular profiling, and immunotherapy present exciting prospects for future exploration, shaping the next era of diagnostic and therapeutic strategies in thyroid cancer research.","PeriodicalId":12107,"journal":{"name":"Expert Review of Endocrinology & Metabolism","volume":" ","pages":"469-477"},"PeriodicalIF":2.7,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141554490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Tirzepatide: unveiling a new dawn in dual-targeted diabetes and obesity management. 替扎帕肽：揭开糖尿病和肥胖症双靶向治疗的新篇章。

IF 2.7

Expert Review of Endocrinology & Metabolism Pub Date : 2024-11-01 Epub Date: 2024-08-28 DOI: 10.1080/17446651.2024.2395540

Syed Arman Rabbani, Mohamed El-Tanani, Ismail I Matalka, Imran Rashid Rangraze, Alaa A A Aljabali, Mohammad Ahmed Khan, Murtaza M Tambuwala

{"title":"Tirzepatide: unveiling a new dawn in dual-targeted diabetes and obesity management.","authors":"Syed Arman Rabbani, Mohamed El-Tanani, Ismail I Matalka, Imran Rashid Rangraze, Alaa A A Aljabali, Mohammad Ahmed Khan, Murtaza M Tambuwala","doi":"10.1080/17446651.2024.2395540","DOIUrl":"10.1080/17446651.2024.2395540","url":null,"abstract":"Introduction: Incretin-based therapies have emerged as effective treatments for type 2 diabetes (T2D) and obesity. However, not all patients achieve optimal outcomes with existing treatments, highlighting the need for more effective solutions.Areas covered: We present a comprehensive evaluation of Tirzepatide (TZP), a novel dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 (GIP/GLP-1) receptor agonist, for managing obesity and T2D. We conducted a systematic search of Cochrane, PubMed, Scopus, and Web of Science databases from inception to April 2024. The focus of the review is on the development and therapeutic potential of TZP, with detailed exploration on pharmacodynamics, pharmacokinetics, clinical efficacy, and safety. Furthermore, it reviews TZP's impacts on glycemic control, weight management, and its potential cardiovascular (CV) benefits.Expert opinion: TZP represents a significant advancement in the dual-targeted approach to treating T2D and obesity. Its unique mechanism of action offers superior efficacy in reducing glycemic levels and body weight compared to existing therapies. New data suggesting improvements in CV outcomes indicate that TZP could set a new standard in the treatment paradigm. While long-term data on efficacy and safety are still forthcoming, current evidence positions TZP as a promising option for patients who have not reached their therapeutic goals with existing treatments.","PeriodicalId":12107,"journal":{"name":"Expert Review of Endocrinology & Metabolism","volume":" ","pages":"487-505"},"PeriodicalIF":2.7,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142079752","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0